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2352-3042/Copyright ª 2014, ChongqAbstract The multifaceted sequence of events that follow fracture repair can be further
complicated when considering risk factors for impaired union, present in a large and growing
percentage of the population. Risk factors such as diabetes, substance abuse, and poor nutri-
tion affect both the young and old, and have been shown to dramatically impair the body’s nat-
ural healing processes. To this end, biotherapeutic interventions such as ultrasound, electrical
simulation, growth factor treatment (BMP-2, BMP-7, PDGF-BB, FGF-2) have been evaluated in
preclinical models and in some cases are used widely for patients with established non-union or
risk/indication or impaired healing (i.e. ultrasound, BMP-2, etc.). Despite the promise of these
interventions, they have been shown to be reliant on patient compliance and can produce
adverse side effects such as heterotopic ossification. Gene and cell therapy approaches have
attempted to apply controlled regimens of these factors and have produced promising results.
However, there are safety and efficacy concerns that may limit the translation of these ap-
proaches. In addition, none of the above mentioned approaches consider genetic variation be-
tween individual patients. Several clinical and preclinical studies have demonstrated a genetic
component to fracture repair and that SNPs and genetic background variation play major roles
in the determination of healing outcomes. Despite this, there is a need for preclinical data to
dissect the mechanism underlying the influence of specific gene loci on the processes of frac-
ture healing, which will be paramount in the future of patient-centered interventions for frac-
ture repair.
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Fracture treatment relies on the timely principles of
restoration of anatomy and appropriate osseous stabiliza-
tion, which will lead to restoration of bone structure and
function.1,2 Despite the intrinsic ability of the body to heal
fractures, patient risk factors can significantly impair
skeletal repair.3 The rate of delayed fracture healing or
non-union is highest amongst subpopulations with specific
risk factors such as smoking, advanced age, steroid use, use
of certain pharmaceuticals (i.e. anti-cancer drugs) and
metabolic diseases such as diabetes mellitus (DM).3 An
increased mechanistic understanding for impaired osseous
healing associated with specific high-risk populations will
provide fundamental information necessary to design a
regenerative approach for fracture patients with specific
risk factors for non-union. This complexity is further
increased when “the patient factor” is introduced. Namely,
each individual has a unique genetic makeup, which in-
fluences the processes of fracture repair. In addition, ge-
netic mutations caused by external patient factors (co-
morbidities, environmental influences) may further distin-
guish healing processes amongst our world’s population as
truly heterogeneous.
Of the 6.2 million fractures sustained in the United
States each year, these patient factors have resulted in a
10% incidence of delayed union or non-union.4 To address
these clinical concerns, there are a number of treatments
available including autologous or allogeneic bone grafts and
a variety of bone substitutes such as demineralized bone
matrix (DBM).5,6 Adjunctive measures such as low intensity
pulsed ultrasound (LIPUS) to provide biomechanical stimu-
lation7 have also been used. More recently, biological fac-
tors including the bone morphogenic proteins (BMPs) have
been successfully used to promote bone repair.8 BMP2
(Infuse) in particular has been administered to patients
with established non-union or risk of non-union due to the
fracture location. While these and other currently available
agents hold promise in accelerating fracture healing, they
have limited usefulness or efficacy and do not account for
the genetic component or “the patient factor”.9,10
The development of a predictive “toolbox” to assess
how individual patients will respond to particular treatment
regimens should be the next leap forward in treating a
growing global population, many of whom have co-
morbidities that increase the likelihood of compromised
bone repair. The collection of preliminary data to construct
this “toolbox” may be garnered through large-scale pre-
clinical studies which examine the genetic influences of
isolated point mutations on bone repair using models of
closed fracture and established non-union. This information
can be used to personalize therapeutic regimens for frac-
ture repair, similar to existing personalized medicine for
genetic screening for certain cancers (i.e. BRCA gene for
breast cancer) and screening for risk of cystic fibrosis in
expected parents.
In this review, we will begin with a brief discussion of
fracture repair, followed by a description of patient fac-
tors, which have been shown to inhibit regenerative pro-
cesses. Several clinically implemented biotherapeutics and
promising gene therapy approaches for patients with theserisk factors will be described and their use/effectiveness
will be discussed. Finally, the potential of patient centered
medicine will be presented, considering potential pitfalls
and alternative paths forward.Bone fracture healing
Following injury, bone has the unique ability to repair itself
through mechanisms similar to its post-natal development
process. Fracture healing involves two distinct but impor-
tant mechanisms leading to bone formation, primary and
secondary fracture healing. Primary fracture healing occurs
when bones unite across the fracture site via direct bone
formation to bridge the gap. This type of healing occurs in
the presence of rigid internal fixation and a near absence of
interfragmentary strain.11 Secondary fracture healing
(endochondral ossification) occurs when there is significant
micro-motion at the fracture site. It is characterized by
responses from the periosteum, marrow, and external soft
tissue that lead to formation of a callus to bridge the gap,
and occurs in three stages: inflammation, repair, and
remodeling.1,2 Despite the sequenced description of these
processes, these phases actually occur in an overlapping
spacial and temporal pattern.
Blunt trauma associated with a fracture results in an
interruption of skeletal integrity, coupled with a disruption
of the normal vascular structures and nutrient flow at the
fracture site. This leads to reduced oxygen tension and
disruption of bone marrow architecture (Fig. 1A). The in-
flammatory phase of fracture healing proceeds with in-
flammatory cell, macrophage, and degranulating platelets
infiltration of the fracture site during hematoma forma-
tion.2,12 Platelets and inflammatory cells within the he-
matoma release several factors that are important for
chemotaxis, proliferation, angiogenesis and mesenchymal
stem cell differentiation into osteoblasts or chondro-
blasts.13,14 The early events that take place during the in-
flammatory phase set the stage for the cartilaginous phase
and the progression of endochondral ossification.
During the cartilaginous phase of healing in a long bone
fracture, two discrete crescent shaped cartilage tissue
masses develop, symmetric to the fracture line (Fig. 1B).
Cartilage, which provides initial stability to the healing
fracture, is produced through a process beginning with
signaling molecule directed differentiation of mesenchymal
cells into chondroblasts. Once chondroblasts become
embedded in the extracellular matrix, they mature to
become chondrocytes. Non-hypertrophic chondrocytes are
capable of proliferation and continue to synthesize carti-
lage matrix. Maturing chondrocytes which previously
expressed aggrecan and type II collagen undergo hypo-
trophy, terminal differentiation, and characteristically ex-
press type X collagen.15 The matrix is subsequently calcified
and remaining cartilage is resorbed, setting the stage for
the bony phase of fracture repair.
Following calcification, the callus is invaded by newly
formed blood vessels. The vasculature provides a conduit
for the recruitment of osteoblastic progenitors, as well as
chondroclasts and osteoclasts needed to resorb the calci-
fied tissue and early mineralized tissue (Fig. 1C). The
Figure 1 The progression of fracture healing (A) injury and hematoma formation (B) cartilaginous callus and intramembranous
bone formation (C) bony/vascularized callus formation (D) callus remodeling and fracture resolution.
Figure 2 Pathologic factors associated with impaired frac-
ture repair.
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produce woven bone within the gap region of the fracture
callus.16 The woven bone produced in this stage acts as a
peripheral buttress, which is subsequently remodeled in
the final phase of fracture healing.
The final stage of fracture healing is characterized by
remodeling of woven bone to form a structure with similar
tissue structure and mechanical integrity of non-fractured
bone (Fig. 1D).16 Despite the efficient design of these bone
healing processes, they may be impaired through substance
abuse, pathologic conditions, estrogen loss, and
malnutrition.
Factors that impair bone fracture healing
The clinical importance of impaired fracture healing cannot
be overemphasized. Several past orthopedic challenges
have been overcome with the advent of collaboration be-
tween basic science and clinical research such as acceler-
ated repair of fracture healing, particularly in the presence
of risk factors associated with increased rate of infection
and non-union. Impaired fracture healing outcomes,
particularly those associated with co-morbidities repre-
sents an ongoing hurdle for initial fracture management.3
Although the fracture repair process is well understood,
relatively little is known about the coordinated regulation
of events necessary to achieve successful repair. Even less
is understood about how this process can fail, leading to
cases of delayed union or non-union. Bone healing generally
proceeds in a highly reproducible manner, producing a tis-
sue virtually indistinguishable from the original bone.
However, certain systemic conditions significantly impair
the body’s ability to repair fractured bone (Fig. 2).
Vitamin D and some of its metabolites have demon-
strated roles in bone metabolism and fracture healing.17
Vitamin D deficiency is known to induce secondary hyper-
parathyroidism, as well as increased bone turnover and
bone mineral loss.18,19 Vitamin D deficiency has been shown
to block formation of mature bone during fracture healing.
Osteoid deposition however, remains unchanged with
Vitamin D deficiency.20 Similar to Vitamin D deficiency, the
deficiency of many other nutrients that influence bone
health and/or signaling can significantly inhibit fracture
healing. Local growth factor deficiencies which include
platelet-derived growth factor (PDGF), vascular endothelial
growth factor (VEGF), insulin-like growth factor-I (IGF-I),
and transforming growth factor-beta (TGF-b) amongst
others have been identified as playing critical roles in the
early stages of the musculoskeletal healing process.21,22
Thus, malnutrition such as Vitamin D deficiency can
significantly impair the processes of fracture repair,
particularly bone turnover. Similar to how nutritional
regulation can influence callus remodeling, hormonalregulation has also been shown to be critical to this stage of
fracture healing.
Estrogen is an important protective hormone for bone
homeostasis and loss of this protection after menopause
contributes to the pathogenesis of postmenopausal osteo-
porosis. Although this estrogen’s protective effect is
thought to be largely mediated by inhibition of bone
resorption, recent evidence suggests that estrogen may
also stimulate osteoblast activity, critical to appropriate
fracture healing.23e25 This provides evidence that in addi-
tion to nutritional regulation, hormonal regulation is
important to the mechanisms of fracture repair, yet
sometimes environmental factors (i.e. substance abuse)
may significantly impair the healing processes.
Clinical and experimental settings have shown a rela-
tionship between smoking and a variety of orthopaedic
conditions, including delayed union and nonunion amongst
human and animal fracture models.26e28 Fracture repair is
slower in smokers compared to non-smokers. The rate of
nonunion also is higher amongst smokers. This observation
has been shown in clinical trials of open and closed tibia
shaft fractures and spinal fusions.26,29,30e32 The negative
impact of smoking on fracture healing could be explained
by nicotine’s inhibition of osteoblast activity33,34 as well as
its constrictive effect on the micro-vasculature.35e37 This
vasoconstrictive effect has been observed during revascu-
larization of cancellous bone graft during spinal fusion.38 It
is also possible that nicotine attenuates cytokine expression
during bone formation.39 In addition to the established in-
hibition of fracture healing with nicotine use, other sub-
stance abuse can also increase the incidence of non-union.
Few studies exist which examine the effects of alcohol
on fracture repair. Available data suggests that alcohol
abuse does not increase the incidence of non-unions,
osteonecrosis, or other complications,40,41 but is associ-
ated with an increase in healing time for fractures with
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observed impairment of fracture callus tissue formation is
deregulation of the Wnt signaling protein b-catenin
signaling, and associated disruption of Wnt-mediated
transcription.42 Although maintenance of nutritional
health and avoidance of environmental risk factors can
reduce the risk of non-union, certain metabolic conditions
can significantly impair several facets of the fracture
healing processes.
Diabetes mellitus is one such condition associated with
impaired fracture healing, presenting a major therapeutic
challenge as over 21.0 million Americans are diagnosed with
Type I/Type II diabetes.43 Impairments associated with the
diabetic osteopathology include local growth factor de-
ficiencies within the DM fracture callus which delay/
compromise healing, advanced glycation end products
(AGEs) which accumulate within the bone and have been
shown to affect osteoblast function and the structural and
mechanical properties of bone, and impaired osteoclasto-
genic regulation at the end of the cartilaginous phase,
leading to accelerated resorption of calcified cartilage.
AGEs are produced when reducing sugars, such as glucose,
react with amino groups in proteins, lipids, and nucleic
acids through a series of reactions forming Schiff bases and
Amadori products.44 The accumulation of AGEs leads to
tissue damage through structural modification of pro-
teins,45 stimulation of cellular responses via receptors
specific for AGE proteins,46 and generation of reactive ox-
ygen intermediates.47,48 In patients with DM, AGE formation
is markedly accelerated because of the increased avail-
ability of glucose and increased oxidative stress. AGEs have
been found to accumulate in bone tissue and affect oste-
oblast function and its structural and mechanical proper-
ties.49,50 In addition to the damaging effects of AGE
accumulation, bone remodeling is significantly impaired in
DM fractures.
Insight into the influence of DM on the extent of osteo-
clastogenesis can be determined from several studies
analyzing the effect of DM upon release and expression of
various inflammatory cytokines critical for osteoclasto-
genesis.51,52 Suzuki et al measured the bone mineral con-
tent and fasting levels of serum intact parathyroid hormone
(i-PTH), intact osteocalcin (i-OC), tartrate-resistant acid
phosphatase (TRAP), and osteoclastogenesis inhibitory
factor/osteoprotegerin (OCIF/OPG) among male type 2
diabetic subjects and their age matched non-diabetic
controls.53 These proteins are essential in both bone ho-
meostasis and fracture healing, and are all potentially
compromised by diabetes. Suzuki et al determined that
serum levels of i-PTH and i-OC were significantly lower in
DM patients than in non-diabetic controls indicative of
reduced bone formation. Serum levels of TRAP were
significantly higher in diabetic patients indicative of
increased osteoclastogenesis. Suzuki et al found no defini-
tive correlation when comparing i-OC and OPG serum levels
within the same group. This was unexpected as expression
of i-OC is known to regulate bone turnover, and OPG may
inhibit osteoclastogenesis. TRAP serum values, associated
with osteoclastogenesis and OCIF/OPG, associated with
vascular physiology and pathology, were both shown to
have a negative correlation with bone mineral density.
Therefore, diabetic individuals with higher TRAP and OCIF/OPG serum levels had lower bone mineral densities than
those with lower serum values. In addition to AGE induced
bone damage and disruption of bone remodeling, metabolic
conditions such as diabetes also increase the risk of infec-
tion following trauma.
Infection still represents a major surgical challenge,
despite improvements in operative techniques and antibi-
otic therapy. Deep infections can result in significant pa-
tient morbidity following open fractures or surgery for
closed fractures. Osteomyelitis, an infection of the bone,
may occur in as many as 5%e18% of operatively managed
closed calcaneal fractures.54,55 Depending on the size of an
open wound, osteomyelitis may arise in up to 27% of cases
with open calcaneal fractures.56 Despite the plethora of
risk factors for mal-union/non-union and with infections as
a secondary complication, the fracture healing processes
can alternatively be enhanced through use of bone healing
adjuncts and potentially by promising gene therapeutic
approaches.Biotherapeutics for fracture repair
The use of locally delivered adjuncts to accelerate bone
fracture healing has truly progressed over the years. With
the remarkable success of BMPs, the orthopedics market
leapt forward. Despite recent advances in technology
(Fig. 3), current Food and Drug Administration (FDA)
approved bone healing adjuncts/therapies either suffer
from risks9,10 including ectopic bone formation (BMPs), or
are reliant on patient compliance (LIPUS).7,57,58 Further,
the costs of each intervention are quite expensive for both
the manufacturer and patient. Unpredictable responses to
these therapies may further be complicated when consid-
ering a diverse population with differing genetic
backgrounds.
As seen with many orthobiologics, growth factors/bi-
ologics such as BMP-2 and BMP-7 (OP-1), platelet derived
growth factor BB (PDGF-BB), and TGF-b demonstrate a
biphasic effect at higher doses, either failing to accel-
erate59 or possibly inhibiting osseous healing.60,61 A study
by Boerckel et al found that bone volume and connectivity
were significantly reduced with increasing doses of re-
combinant human bone morphogenic protein 2 (rhBMP-2),
above 1 mg rhBMP-2 in a critical size segmental defect rat
model at 12 weeks post-osteotomy.60 Boerckel et al found
that effective and biphasic dosages of rhBMP-2 were
dependent on the delivery mechanism.60 In contrast, clin-
ical results for OP-1 reported no advantage in treating tibial
non-unions with rhBMP-7 compared to over autograft con-
trols.61 As such, despite promising results for BMPs in
fracture repair, there is still a need to optimize treatment
regimens and explore alternative approaches to combat
non-union.
With this under consideration, alternative orthobio-
logics, administered at low doses or specific to bone have
investigated in clinical trials. Based on the effectiveness of
parathyroid hormone (PTH) to increase osteoblastic activity
and bone mineral density in animal studies of osteopo-
rosis,62 a clinical trial was initiated to evaluate the efficacy
of oral PTH (1e34) (teriparatide) to treat fracture in post-
menopausal women following fracture of the distal
Figure 3 Biotherapeutics for fracture repair.
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significantly shorter time to healing, but the 40 mg was not
significantly different from the control.62 As a result of the
clinical trial success of PTH for fracture healing in post-
menopausal women, other osteoporotic medications were
investigated for the same indication. Despite promising
early data in preclinical models, an anti-sclerostin antibody
romosozumab phase II clinical trial for another pharma-
ceutical was recently abandoned, in favor of focusing ef-
forts on more favorable data on osteoporosis.63 A large
multicenter study investigating the bisphosphonate risedr-
onate, to repair fractures found that administration of
risedronate during surgery did not significantly alter the
progression of intertrochanteric fracture repair or inci-
dence of complications.64 In contrast to the results of the
risedronate trial, following early promising evidence, a
phase III clinical trial involving injection of the bisphosph-
onate denosumab65 in a tibial fracture model, is currently
underway in China. In addition to the PTH, sclerostin
antibody and bisphosphonate clinical trials for fracture
repair in post-menopausal women, clinical trials using
growth factors have also been recently initiated.
Clinical trials in Japan evaluating the fracture healing
efficacy of local administration of fibroblast growth factor 2
(FGF-2) into the fracture gap of tibial shaft fractures
following intramedullary nailing, revealed that significantly
more patients achieved bony union compared to the pla-
cebo group at 24 weeks post-administration, with no
adverse events noted with the higher dose of FGF-2.66
Similarly, large scale human clinical trial in periodontal
osseous defects found that recombinant human PDGF-BB
had a biphasic effect at 1 mg/ml on bone mineralization
within the defect region, compared to the 0.3 mg/ml group
at 6 months post-treatment.67 Besides these promising
treatment modalities, there are many other alternatives
that are currently being investigated in preclinical models.
Various preclinical animal models have been established
and used to investigate bone fracture healing and to facil-
itate the preclinical evaluation of new treatment options
such as osteoinductive drugs. Animal models are indis-
pensable for demonstrating the benefit of any new modality
sufficiently different from the standard treatment. Addi-
tionally, preclinical testing of new treatments or devices is
required to prove efficacy and safety. The US Food and Drug
Administration (FDA) recommend that agents be evaluated
in at least two different animal species. Experimental an-
imal models that mimic blunt trauma have been developed.
Many of these models are described in the fracture repairliterature, and have been implemented to investigate the
local and systemic delivery of pharmaceutical agents to
enhance fracture repair.
The numerous animal studies on this subject differ in
terms of species, fracture site, and fixation method. Rabbit
models have been used to study the effect of transforming
growth factor-b (TGF-b),22,68 fibroblast growth factor-1
(FGF-1), and fibroblast growth factor-2 (FGF-2)69,70 on
tibia fracture repair. Dogs, baboons, monkeys, pigs, sheep,
rabbits, and goats all have been used to study the effects of
exogenous growth factors and cytokines on fracture
healing.71e75 However, the rodent closed femur fracture
model described by Bonnarens and Einhorn76 is the most
frequently used model due to fracture reproducibility,
availability or rats in large numbers, and
affordability.77e86,21 The success and limitations of these
and other biotherapeutics in translational animal models
and in some patients lead to the investigation of gene
therapy/cell therapy approaches to potentially improve the
efficiency of augmented fracture repair.Gene therapy/cell therapy approaches to bone
healing
Recent advances in tissue engineering and cell biology have
opened avenues to improve our methods for enhancement
of bone repair especially in large bone defects. Various
gene therapy techniques using HSV, Adenovirus, Lentivirus
or AAVs have been successfully used to deliver osteoin-
ductive agents to the site of fracture healing. Delivery of
the cDNA of a number of BMPs using in vivo and ex vivo
transfer techniques have demonstrated successful
enhancement of the healing of critical sized defects in
preclinical models.87 Other transgenes including VEGF
PDGF, FGF, Osterix, Nell-1 and Runx-2 have also been used
with success in the animal models of fracture and long bone
defect healing.88 Virk et al introduced a “same day” gene
therapy protocol using a Lentiviral vector with a 2-
h transduction step to overexpress BMP-2 in fresh rat
bone marrow mononuclear cells and showed the efficacy of
this method in healing 6-mm long critical-sized defects in
the rat femur.89 They also compared the use of the Lenti-
viral and Adenoviral vector-based ex vivo gene therapy
methods. They showed superior bone healing using the
Lentiviral delivery of BMP-2 and postulated that prolonged
release of BMP-2 in a more physiologic dose was responsible
for improved defect healing.90 Betz et al demonstrated that
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after induced fracture, significantly enhanced radiological
union and biomechanical strength, following critical-size
segmental defects.91 Despite the promise of gene therapy
to overcome the difficulties of challenging bone repair
scenarios, the use of these techniques in humans is limited
due to the safety concerns such as mutagenic or carcino-
genic nature of these genetic modifications.
To address the safety concerns associated with gene
therapy, Alaee et al developed a dual gene expression
vector overexpressing BMP-2 and HSV-Tk in an effort to
enhance the safety of ex vivo gene therapy by killing the
transduced cells with Ganciclovir after the bone healing
process was completed. They showed reduced numbers of
viable transduced cells in a mouse critical sized defect
model, but complete elimination of these cells was not
achieved.92 In summary, there is a need for development of
effective gene therapy strategies with established safety
profiles in well controlled trials before they can be used in
the humans. A promising alternative to gene therapy is the
application of novel cell-based therapeutic strategies.
Cell-based therapies including embryonic stem cells for
bone regeneration purposes have also been evaluated by
many investigators. Tianai et al used an osteoporosis
related impaired fracture model in mice and showed
enhanced fracture healing after 4 weeks of implanting
murine ES-derived osteoblasts.93 Enhanced healing of cal-
varial defects in immune-compromised mice after implan-
tation of human ES cells was reported by Kuhn et al.94 They
showed that the hESCs were able to recapitulate the
mesenchymal developmental pathway and were able to
repair the bone defect semi-autonomously without preim-
plantation differentiation to osteo- or chondroprogenitors.
There are still concerns regarding the efficacy of the cell
based therapies as well as ethical issues surrounding the
use of embryonic stem cells. More refinements in these
cell-based strategies are also warranted before they can be
used as a viable option for enhanced bone formation in
humans. These gene/cell therapy approaches continue the
propagation of grouping patients based on case indications
and pathologic diagnosis. Despite this, there is growing
evidence of a genetic component to fracture repair.Genetic components of fracture repair
Although orthobiologic treatments present options and will
advance in the future, the genetic components of fracture
healing should be considered to optimize the development
of patient centered othobiologics. Several studies have
shown that there exists a genetic predisposition to fracture
non-union which is complicated by patient risk factors.95e98
A study examining single nucleotide polymorphisms (SNPs)
in the BMP signaling cascade found that advanced age was
an important covariate in development of atrophic non-
union and that SNPs located on NOGGIN and SMAD6 (in-
hibitors of the BMP pathway) are associated with a greater
risk of fracture non-union.95 Similarly, others have shown a
significant association between SNPs of the PDGF gene
(particularly PDGF-A and MMP-13) and incidence of non-
union for lower extremity fractures.98 SNPs have also
been shown to be important influencers of fracture risk,based on genetic background in patients.99 This emphasizes
the need for large-scale preclinical studies, which evaluate
the mechanisms underlying genetic predisposition to
impaired fracture healing and identifying novel targets
associated with SNP-impaired healing amongst preclinical
models.
The early clinical evidence supporting the importance of
genetic variations on fracture repair, prompted preliminary
preclinical studies, comparing the ability of various strains
of mice to heal surgically induced fractures.100,101 Mani-
grasso and O’Connor compared C57BL/6NTac (B6/N) with
DBA/2NTac (D2/Tac) and C3H/HeNTac (C3H/Tac) mouse
stains and found that the B6/N strain exhibited an accel-
erated rate of healing compared to the other two strains,
with C3H/Tac mice healing the slowest.100 In another study,
Jepsen and colleagues compared fracture healing in the
C57BL/6J (B6) with C3H/HeJ (C3H) and A/J mice. They
found that B6 and A/J strains exhibited faster healing
compared to C3H based on mechanical properties of healed
bones101 and that B6 mice expressed the highest percent-
age of cartilage gene products. This was associated in-
creases in chondrocyte maturation and hypertrophy. In
contrast, C3H mice had a premature osteogenic response,
and an associated slower healing rate than the other
strains. Although these preclinical studies were the first to
demonstrate a genetic component to fracture healing, they
did not evaluate the influence of specific SNPs of impaired
fracture healing.
There are limitations to clinical studies investigating SNP
variations in the general population that create a need for
sophisticated preclinical studies which dissect and evaluate
the influence of individual SNPs, independent of patient
risk factors (which may not be previously diagnosed). One
such limitation is that clinical studies are designed to be
non-invasive, and thus are limited in their assessment of
biomechanical tissue integrity, high-resolution imaging ca-
pacity, and the availability of histological/immunohistoch-
mical tissue samples. For these reasons, the mouse model,
which can be targeting specific gene loci, presents a unique
translational model to study the influences of SNPs on
fracture healing in the absence or presence of fracture
repair. Future studies using mouse models to evaluate the
influence of specific gene loci in fracture repair may serve
as a stepping stone to transition to higher order trans-
lational animal models, and further the transition from
bench to bedside.Conclusions
With the plethora of genetic, pathologic, and environ-
mental factors that pose a risk for proper fracture healing,
there has been substantial characterization regarding the
effects of these risk factors on fracture healing. However,
there is still an urgent need to enhance the healing process
and eradicate the incidence of non-unions. As such, the
development of adjuncts that are designed to be effective
for individual patients is of paramount importance. The
concept of a single gene regulating a complex phenomenon
such as bone repair must transition into a more compre-
hensive assessment of the causes underlying impaired
fracture healing. This is underscored by various patient
146 H. Drissi et al.factors and co-morbidities that contribute to delaying the
repair process. Thus, future studies ought to link fracture
repair with genetic variability. Studies using genetically
diverse populations of mice can indeed bring unique insight
into the contribution of genomics to impaired or enhanced
fracture healing. Such studies are now possible using the
collaborative crosses or the diversity outcross mice gener-
ated by a consortium of mouse geneticists. These studies
will also permit sub-analyses regarding the effects of risk
factors for impaired fracture healing and their association
with specific single nucleotide polymorphisms. Ideally,
strategies that can be tuned to the patients’ genetics and
potential risk factors, would create optimized orthobio-
logics for what we could envision as “personalized
orthopaedics”.Conflicts of interest
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